HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Is there an optimal target for disparities research?
-
- The right target: how survival is affected by race/ethnicity, socioeconomic status
- ATA revised guidelines for thyroid nodules, differentiated thyroid cancer
- Initial radiotherapy, chemotherapy produced equivalent results with anaplastic glioma
- Role of KRAS/BRAF in metastatic colorectal cancer still emerging
- Recognizing gemcitabine-induced thrombotic thrombocytopenic purpura Amit Mehta, MD
- Practice pearls for providing leadership through teaching
- The utility of PET/CT in monitoring treatment response and detecting unusual metastases in esophageal cancer Munir Ghesani, MD, FACNM; Eric O. Gamboa, MD; Seth Cohen, MD
- VTE did not affect survival in lenalidomide/ dexamethasone-treated multiple myeloma
-
- ACCORD 12/0405 Prodige 2: Radiation dose intensification with capecitabine/oxaliplatin may be optimal for rectal adenocarcinoma
- Adjuvant radiotherapy decreased risk for lymph node cancer recurrence in high-risk melanoma
- CHAMPION PLATFORM: Cangrelor not superior to placebo for reduction of combined study endpoint
- Concurrent CRT no better than neoadjuvant chemotherapy for nasopharyngeal carcinoma
- Dose-painted intensity-modulated radiation therapy reduced toxicity for anal canal cancer
- GU, GI toxicity due to proton therapy minimal for prostate cancer
- PCI reduced risk for developing brain metastases, increased memory loss in NSCLC
- Tumor volumes derived from PET/CT smaller than those derived from CT alone
-
- Educate patients and families for the end of life Biren Saraiya, MD